Phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11J

Experimental Data Snapshot

  • Resolution: 1.72 Å
  • R-Value Free: 0.221 
  • R-Value Work: 0.198 
  • R-Value Observed: 0.200 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha Mitogen-Activated Protein Kinase Inhibitors

Hynes, J.Dyckman, A.J.Lin, S.Wrobleski, S.T.Wu, H.Gillooly, K.M.Kanner, S.B.Lonial, H.Loo, D.McIntyre, K.W.Pitt, S.Shen, D.R.Shuster, D.J.Yang, X.Zhang, R.Behnia, K.Zhang, H.Marathe, P.H.Doweyko, A.M.Tokarski, J.S.Sack, J.S.Pokross, M.Kiefer, S.E.Newitt, J.A.Barrish, J.C.Dodd, J.Schieven, G.L.Leftheris, K.

(2008) J Med Chem 51: 4-16

  • DOI: https://doi.org/10.1021/jm7009414
  • Primary Citation of Related Structures:  
    2RG5, 2RG6

  • PubMed Abstract: 

    A novel structural class of p38 mitogen-activated protein (MAP) kinase inhibitors consisting of substituted 4-(phenylamino)-pyrrolo[2,1- f][1,2,4]triazines has been discovered. An initial subdeck screen revealed that the oxindole-pyrrolo[2,1- f][1,2,4]triazine lead 2a displayed potent enzyme inhibition (IC 50 60 nM) and was active in a cell-based TNFalpha biosynthesis inhibition assay (IC 50 210 nM). Replacement of the C4 oxindole with 2-methyl-5- N-methoxybenzamide aniline 9 gave a compound with superior p38 kinase inhibition (IC 50 10 nM) and moderately improved functional inhibition in THP-1 cells. Further replacement of the C6 ester of the pyrrolo[2,1- f][1,2,4]triazine with amides afforded compounds with increased potency, excellent oral bioavailability, and robust efficacy in a murine model of acute inflammation (murine LPS-TNFalpha). In rodent disease models of chronic inflammation, multiple compounds demonstrated significant inhibition of disease progression leading to the advancement of 2 compounds 11b and 11j into further preclinical and toxicological studies.

  • Organizational Affiliation

    Department of Immunology Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA. john.hynes@bms.com

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 14366Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for Q16539 (Homo sapiens)
Explore Q16539 
Go to UniProtKB:  Q16539
PHAROS:  Q16539
GTEx:  ENSG00000112062 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ16539
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on 287

Download Ideal Coordinates CCD File 
B [auth A],
C [auth A]
C25 H26 N6 O3
Binding Affinity Annotations 
IDSourceBinding Affinity
287 BindingDB:  2RG6 IC50: 2.2 (nM) from 1 assay(s)
EC50: 10 (nM) from 1 assay(s)
PDBBind:  2RG6 IC50: 2.2 (nM) from 1 assay(s)
Binding MOAD:  2RG6 IC50: 2.2 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.72 Å
  • R-Value Free: 0.221 
  • R-Value Work: 0.198 
  • R-Value Observed: 0.200 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 69.141α = 90
b = 71.431β = 90
c = 80.531γ = 90
Software Package:
Software NamePurpose
HKL-2000data reduction
HKL-2000data scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

  • Released Date: 2008-01-15 
  • Deposition Author(s): Sack, J.S.

Revision History  (Full details and data files)

  • Version 1.0: 2008-01-15
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2024-02-21
    Changes: Data collection, Database references, Derived calculations